Volvo EX90 Electric SUV Will Feature Seoul Semiconductor’s SunLike LED Lighting
18.4.2023 16:00:00 EEST | Business Wire | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ:046890), a global optical semiconductor company, has announced that the new Volvo EX90 Electric SUV will feature its SunLike LED lights. This is the first application of the SunLike technology with sun spectrum in production vehicles.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230418005618/en/
Volvo EX90 featuring the SunLike technology (Left) / Comparative graph of color gamuts between SunLike and general LEDs (Right) (Graphic: Business Wire)
SunLike, developed and mass-produced by Seoul Semiconductor for the first time in the world, is a healthy light technology that replicates natural light, protecting the 24-hour biological cycle of a human body. For the past five years, Seoul Semiconductor carried out multiple clinical trials with Harvard University in the United States, the University of Basel in Switzerland, and Seoul National University in Korea, confirming that the use of the solar spectrum, SunLike, can make improvements in myopia, regenerate cells, improve memory, and replicate natural colors.
NEARSIGHTEDNESS IMPROVEMENT
Not all lights are the same, and not all lightings are the same. The closer it is to natural light, the better it is. Light is a mass of particles with energy, so the longer our eyes are exposed to high levels of blue light with high energy, there is a greater chance of damaging our photoreceptor cells and developing myopia. This is why children in Asia who spend more time indoors than outdoors under natural light have a high prevalence of myopia.
According to the “Recovery From Form-Deprivation Myopia in Chicks Is Dependent Upon the Fullness and Correlated Color Temperature of the Light Spectrum(2020)” by Singapore Eye Research Institute (SERI), myopia can be improved by using SunLike.
CELL REPRODUCTION
Natural light affects sleep as well. Evening sunlight promotes the secretion of melatonin which helps to sleep. They say more than 70% of our 60 trillion body cells regenerate while we sleep. Seoul Semiconductor confirmed through the “Effect of daylight LED on visual comfort, melatonin, mood, waking performance and sleep (2019)” conducted by the University of Basel in Switzerland that SunLike lighting improves sleep quality compared to conventional LEDs.
MEMORY IMPROVEMENT
Getting a good night sleep reduces the possibility of building up toxins in the brain, improving memory and concentration. Seoul Semiconductor confirmed through the “Daytime Exposure to Short Wavelength-Enriched Light Improves Cognitive Performance in Sleep-Restricted College-Aged Adults (2021)” conducted by Harvard Medical School that problem-solving skills improved by 5% and speed increased by 3.2 folds when SunLike lighting was used.
COLOR REPLICATION
Conventional LED with CRI 90 have a 90% color gamut of 14 colors in high CRI 90 (sunlight 100). However, SunLike has a 95% color gamut of all 99 colors. This means that it is closest to the color seen under natural sunlight.
According to Dan Fidgett, Volvo’s head of materials and colors, “By utilising the spectrum of light emitted from the SunLike LEDs, the progressive materials and interior design of the Volvo EX90 stand out more clearly and without colour distortion” Fidgett also added, “Bringing in SunLike LEDs to the interior of the Volvo EX90 is another illustration of our ambition to bring in innovative technology to deliver a renewed premium in-car experience for our customers”.
For all interior light fixtures of Volvo EX90, SunLike will be installed. Already widely used by large museums and art galleries around the world, SunLike LEDs have been used to reveal the color and texture of Pompeii ruins’ murals in Italy.
N. Kobayashi, SunLike’s key developer and Seoul Semiconductor’s technical advisor (former CEO of TMAT), explains, “SunLike is a differentiated, high-quality ‘healthy lighting’ that has all the benefits of natural light. It is widely being used in various places, such as residential spaces where people rest, hospitals that lack outdoor activities, schools where concentration and vision health are important, horticultural greenhouses that require light, etc”.
In addition to Volvo EX90, SunLike will also equip ‘Polestar 3’ which shares the same technology base.
About Seoul Semiconductor
Seoul Semiconductor is the world’s second-largest global LED manufacturer, a ranking excluding the captive market, and has more than 18,000 patents. Based on a differentiated product portfolio, Seoul offers a wide range of technologies, and mass produces innovative LED products for indoor and outdoor lighting, automotive, IT products, such as mobile phones, computer displays, and other applications, as well as the UV area. Seoul’s world’s first development and mass production products are becoming the LED industry standard and leading the global market with a package-free LED, WICOP; a high-voltage AC-driven LED, Acrich; an LED with 10X the output of a conventional LED, nPola; a cutting edge ultraviolet clean technology LED, Violeds; an all-direction light emitting technology, filament LED; a natural sun spectrum LED, SunLike; and more. For more information, please visit www.seoulsemicon.com/en, YouTube, LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230418005618/en/
Contact information
Seoul Semiconductor Co., Ltd.
Jinseop Jung
+82-1566-2771
jjs8732@seoulsemicon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 15:00:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.
Fortegra Completes Acquisition by DB Insurance29.5.2026 23:30:00 EEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 23:01:00 EEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
